Introduction
The novel ketolide HMR 3647 (formerly called RU 66647) belongs to a new semi-synthetic 14-membered ring macrolide class of antimicrobial agents. Ketolides are characterized by a 3-keto group on the erythronolide A ring instead of the usual -L-cladinose moiety. 1 Preliminary investigations have demonstrated that ketolides possess a broad antibacterial spectrum similar to that of erythromycin A 2 and with additional activity against inducible MLS B -resistant pneumococci, methicillin-resistant Staphylococcus aureus, Haemophilus influenzae and enterococci. 3 Their activity is similar to those of the macrolides in that it includes the 'atypical' pathogens, Chlamydia spp., Legionella spp. and Mycoplasma spp. 4 The activity of the ketolides against macrolide-resistant microorganisms is of immense value as the widespread clinical use of macrolides has led to resistance in several species. For example, 95% of methicillin-resistant S. aureus and 51% of penicillin-resistant Streptococcus pneumoniae are macrolide-resistant. 5 HMR 3647 possesses pharmacodynamic properties similar to those of azithromycin, that is, it exhibits concentration-and inoculum-dependent bacteriostatic activity and has a considerable postantibiotic effect (PAE). 6 Additionally, the activity of the ketolides is less influenced by pH than are the activities of macrolides. 7 In these investigations, we compared the in-vitro activity of HMR 3647 with a range of relevant antimicrobials (three macrolides, one -lactam and one fluoroquinolone) against a wide range of pathogens, Grampositive, Gram-negative and anaerobic bacteria, including strains with characterized resistance patterns and Chlamydia spp. Additionally, the effects on the in-vitro activity of HMR 3647 of increasing the inoculum and the presence of human serum were investigated.
Materials and methods

Antimicrobial agents
The antimicrobial agents investigated were obtained from the following sources: HMR 3647, erythromycin A, roxithromycin, clarithromycin and levofloxacin from Hoechst Marion Roussel (Romainville, France), amoxycillin and clavulanic acid from SmithKline Beecham (Worthing, UK), ciprofloxacin from Bayer AG (Wuppertal, Germany) and doxycycline from Wyeth Laboratories (Gosport, UK). These antimicrobial agents were stored and prepared throughout these investigations using the manufacturers' guidelines. cfu (all strains) and, for a few selected strains, an increased inoculum of 10 6 cfu was employed using a multipoint inoculator (Denley Instruments, Billinghurst, UK). Plates were incubated either in air at 35-37°C for 18-24 h or, for fastidious bacteria, in an atmosphere enriched with 4-6% carbon dioxide or, for anaerobic bacteria, in an anaerobic cabinet (Don Whitley Scientific Ltd, Skipton, UK) containing an atmosphere of 80% nitrogen, 10% hydrogen and 10% carbon dioxide. The MIC was defined as the lowest antimicrobial concentration inhibiting growth (two or three colonies were ignored). Amoxycillin and clavulanic acid were combined in a ratio of 2:1 and the results were reported in terms of the amoxycillin MIC.
Effect of human serum on the in-vitro activity of HMR 3647
The effect of human serum on both the MICs and MBCs of HMR 3647 was investigated for two strains of each of the following organisms; S. aureus (methicillin-sensitive), S. pneumoniae, Group A streptococci, Moraxella catarrhalis, Enterococcus faecalis and Enterococcus faecium. A microdilution method 8 was employed (with a final inoculum of 5 10 5 cfu/mL) using Iso-Sensitest broth alone (Oxoid) or with either 20% or 70% (v/v) pooled human serum (Bradsure Biologicals, Market Harborough, UK) and supplemented for fastidious bacteria as described previously. Following incubation, 25 L of broth culture was subcultured on to appropriate antimicrobial-free media for MBC determinations. The MBC was defined as the lowest antimicrobial concentration at which there was no growth (99.9% lethality).
Chlamydia susceptibility testing
The in-vitro activity of HMR 3647 (in McCoy cells) against six clinical strains of Chlamydia trachomatis (from both ocular and genital specimens), a strain of Chlamydia psittaci and a reference strain of Chlamydia pneumoniae was investigated in comparison with those of erythromycin A, roxithromycin, doxycycline and levofloxacin. Briefly, the method employed was an adaptation of that of Webberley and co-workers. 9 McCoy cells were inoculated with approximately 1000 inclusion-forming units of chlamydia. They were then exposed to various dilutions of the antimicrobials and incubated in 4-6% CO 2 at 35-37°C for 48 h. The cultures were then stained by direct immunofluoresence using Imagen chlamydia test reagent (Dako Diagnostics Ltd, Ely, UK). The MIC was defined as the lowest antimicrobial concentration that inhibited the development of inclusion bodies, and the minimum lethal concentration (MLC) was defined by the absence of inclusion bodies after a further 48 h incubation in antimicrobial-free medium. 
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Results
The in-vitro antimicrobial activities of HMR 3647 and the other antimicrobial agents are shown in Table I . The results for the type cultures were within one dilutional step of the expected MICs for antimicrobials where this information was known (data not shown). Both methicillin-sensitive and methicillin-resistant S. aureus were more susceptible to HMR 3647 (MIC 90 s of 0.25 and 0.5 mg/L, respectively) than any of the macrolides studied (MIC 90 s 128 mg/L). Among the methicillin-resistant staphylococci tested were macrolide-and quinoloneresistant strains. Of the 42 erythromycin-resistant strains, five were apparently cross-resistant to HMR 3647 (MIC 128 mg/L); these strains were also resistant to roxithromycin and clarithromycin. Additionally, against methicillin-sensitive and -resistant S. aureus, HMR 3647 was four and 32 times, respectively, more active than amoxycillin-clavulanate and HMR 3647 was eight and 100 times, respectively, more active than ciprofloxacin. HMR 3647 and the macrolides studied had little activity against Staphylococcus epidermidis (MIC 90 128 mg/L), whereas amoxycillin-clavulanate and ciprofloxacin were equally active (MIC 90 1 mg/L). HMR 3647 was more active than macrolides and two to four times more active than amoxycillin-clavulanate and ciprofloxacin against Staphylococcus saprophyticus. Against S. pneumoniae, enterococci and peptostreptococci, HMR 3647 had the greatest activity of the antimicrobials tested, whereas against M. catarrhalis HMR 3647 had only similar activity to that of its comparators. Included amongst the S. pneumoniae tested were strains with resistance to either penicillin G, erythromycin A or quinolones and amongst the enterococci were vancomycin-resistant strains; HMR 3647 demonstrated activity against all these strains. Against Group B streptococci and 'Streptococcus milleri', HMR 3647 was only marginally more active than the macrolides studied and more active than either amoxycillin-clavulanate or ciprofloxacin. Group A streptococci were equally susceptible to HMR 3647 and amoxycillin-clavulanate, but less susceptible to the other antimicrobials studied. Additionally, HMR 3647 was four to eight times more active than the macrolides against H. influenzae (including -lactamase producers), but not as active as either amoxycillin-clavulanate or ciprofloxacin. Against Neisseria spp., HMR 3647 was more active than the macrolides and amoxycillin-clavulanate, but not ciprofloxacin. Clarithromycin was more active than HMR 3647, which had similar activity to the other antimicrobials, against Bacteroides fragilis. Against Clostridium spp. HMR 3647 had greater activity than the macrolides and ciprofloxacin, but equal activity to that of amoxycillin-clavulanate.
A final inoculum of 10 6 cfu was used for a few selected strains of S. aureus, E. faecalis, M. catarrhalis, 'S. milleri' and Neisseria meningitidis. In general, an increase in inoculum from 10 4 to 10 6 cfu had little effect on the MICs of HMR 3647. However, the MICs for two strains each of S. aureus, E. faecalis and 'S. milleri' were increased by eight times (data not shown).
The effect of human serum on the in-vitro activity of HMR 3647 was investigated on selected organisms and generally neither the inhibitory nor the bactericidal activity of HMR 3647 was affected by the presence of either 20% or 70% (v/v) human serum (MICs and MBCs were equivalent to or within one or two dilution steps of those in broth). However, the effect of serum may be dependent on the species, as the HMR 3647 MBCs for Group A streptococci increased four-fold in the presence of 70% human serum and the HMR 3647 MIC for one strain each of S. aureus and E. faecium decreased with increasing concentration of serum. The comparison of the antichlamydial activity of HMR 3647 with those of commonly used antichlamydial antimicrobials demonstrated that the lethality of HMR 3647 was generally greater than that of its comparators (Table  II) . However, the MICs of HMR 3647 were similar to those of doxycyline, but two to eight times lower than those of erythromycin, roxithromycin and levofloxacin.
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Discussion
In general, the HMR 3647 in-vitro activity data presented here are in agreement with limited preliminary studies of ketolides. 2, 3 In particular, it was noted that HMR 3647 possesses a broad antibacterial spectrum similar to that of erythromycin A, but with additional outstanding activity against multiresistant pneumococci (including penicillinand erythromycin-resistant strains), H. influenzae and enterococci. We also demonstrated that against strains susceptible to macrolides, its activity is one to two orders of magnitude higher than those of clarithromycin and erythromycin; this is in agreement with the data of Agouridas et al. 3 Staphylococci (except S. epidermidis) were more susceptible to HMR 3647 than any other compound tested. However, cross-resistance to HMR 3647 (MIC 128 mg/L) was observed with some strains of macrolide-and quinolone-resistant MRSA. This is in agreement with the work of Kitzis and co-workers 10 who found the activity of a ketolide to be reduced with staphylococci that were constitutively MLS B -resistant. However, Barry et al. 11 observed that the ketolide HMR 3647 had activity against strains of streptococci that were constitutively MLS Bresistant. In addition, cross-resistance to HMR 3647 was not noted with either multiresistant streptococci or enterococci. Ketolides are therefore the first members of the macrolide class to have significant activities against erythromycin-resistant pneumococci. In-vivo studies also demonstrated the potential of HMR 3647 against macrolideresistant S. pneumoniae. 12, 13 Additionally, unlike previous macrolides, HMR 3647 demonstrates significant activity against H. influenzae. Our data demonstrated that HMR 3647 exhibited anaerobic activity similar to that observed with the ketolide RU 004 by Ednie et al. 14 A lack of inoculum effect up to 10 6 cfu was also observed by Agouridas et al. 7 Preliminary studies have shown that ketolides penetrate well into eukaryotic cells, reaching intracellular levels considerably higher than their extracellular concentration 15 and therefore in addition to their antichlamydial activity they may be useful in the treatment of other intracellular pathogens.
In summary, the in-vitro properties of HMR 3647 presented here indicate that it has a potential as an oral agent for the treatment of respiratory tract infections and Gram-positive coccal infections and that additional clinical research into this new macrolide is warranted.
